Ipsen Strengthens Rare Disease Pipeline with €700m Memo Therapeutics Acquisition

The acquisition adds first-in-class BK polyomavirus candidate potravitug as Ipsen continues an aggressive week of dealmaking following its Kartos Therapeutics takeover.

Ipsen has agreed to acquire Swiss rare disease biotech Memo Therapeutics in a deal worth more than €700 million, adding a promising late-stage rare disease programme to its pipeline and continuing its recent acquisition drive.

The transaction follows just days after Ipsen announced its $1.75 billion acquisition of Kartos Therapeutics, signalling an increasingly active business development strategy focused on high-value specialist medicines.

A Potential First-in-Class Therapy for Kidney Transplant Patients

The centrepiece of the acquisition is potravitug, Memo's lead clinical asset targeting BK polyomavirus-associated nephropathy (BKPyVAN).

BKPyVAN is a serious complication that can develop in kidney transplant recipients when the normally dormant BK virus reactivates as a result of immunosuppressive therapy.

Current treatment options are limited, with clinicians often forced to reduce immunosuppressive medication to control the virus, increasing the risk of transplant rejection and long-term graft loss.

Potravitug has been designed to address this unmet need by targeting the virus directly.

The monoclonal antibody binds to the VP1 capsid protein, preventing the virus from attaching to and entering healthy cells, with the aim of stopping viral replication before kidney damage occurs.

Late-Stage Development Underway

Memo plans to launch its pivotal SAFE KIDNEY III Phase III trial later this year.

The programme builds on encouraging results from the earlier SAFE Kidney II study, where potravitug enabled significantly more patients to achieve low or undetectable viral loads compared with placebo.

If successful, the therapy could become the first targeted treatment approved specifically for BKPyVAN, representing a significant advance for kidney transplant care.

The candidate has already received both Fast Track designation from the US Food and Drug Administration and Orphan Drug designation in both the US and Europe.

Deal Structure Reflects Confidence in Future Success

Under the agreement, Ipsen will pay €200 million upfront when the transaction closes, which is expected during the third quarter of 2026.

Memo shareholders could receive more than €700 million in additional milestone payments linked to the programme's clinical development, regulatory approvals and future commercial performance.

The heavily milestone-based structure allows Ipsen to limit upfront risk while providing substantial upside if potravitug reaches the market.

Building Momentum Through Targeted Acquisitions

The Memo acquisition follows Ipsen's purchase of Kartos Therapeutics, which added Phase III myelofibrosis candidate navtemadlin to its oncology pipeline.

Together, the two acquisitions demonstrate Ipsen's strategy of acquiring advanced clinical-stage assets capable of delivering near- to medium-term growth across specialist therapeutic areas.

Rather than pursuing broad portfolio expansion, the company continues to focus on targeted acquisitions addressing diseases with significant unmet clinical need.

Summary

Ipsen has agreed to acquire Memo Therapeutics in a deal worth more than €700 million, strengthening its rare disease pipeline with the addition of potravitug, a potential first-in-class therapy for BK polyomavirus-associated nephropathy.

Combined with its recent acquisition of Kartos Therapeutics, the transaction highlights Ipsen's growing focus on late-stage, high-value assets that could address significant unmet medical needs while supporting the company's long-term growth strategy.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com